Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Heat shock proteins (HSPs) are vital for cellular protein homeostasis.
• Cancer cells exploit HSPs, such as HSP90, for survival and proliferation.
• HSP90 inhibitors have shown preclinical anticancer activity but lack clinical approval.

Purpose of the Study:

• To review the challenges in targeting HSPs, particularly HSP90, in cancer therapy.
• To suggest strategies for overcoming clinical development hurdles for HSP-targeted agents.
• To provide guidelines for future development of HSP-targeted cancer drugs.

Main Methods:

• Literature review of HSPs in cancer.
• Analysis of clinical trial data for HSP90 inhibitors.
• Synthesis of lessons learned from HSP90 inhibitor development.

Main Results:

• HSPs, especially HSP90, are co-opted by cancer cells to promote survival.
• Over 20 HSP90 inhibitors have entered clinical trials with limited success.
• Significant challenges impede the clinical translation of HSP-targeted therapies.

Conclusions:

• Targeting HSPs remains a promising strategy for cancer treatment.
• Overcoming specific clinical challenges is crucial for realizing the potential of HSP inhibitors.
• Future development requires a refined approach based on past experiences with HSP90 inhibitors.